Subtopic Deep Dive
Neuroblastoma Genomic Profiling
Research Guide
What is Neuroblastoma Genomic Profiling?
Neuroblastoma genomic profiling involves whole-genome sequencing, detection of hyperdiploidy, and identification of segmental chromosome aberrations like N-myc amplification to reveal tumor heterogeneity and therapeutic targets.
This subtopic focuses on genomic analyses linking DNA copy number variations to clinical outcomes in neuroblastoma. Key findings include N-myc amplification correlating with advanced disease stages (Brodeur et al., 1984, 2255 citations). Over 10 foundational papers document these profiles, with integrative studies tying aberrations to risk stratification.
Why It Matters
Genomic profiling identifies actionable alterations such as N-myc amplification, enabling risk-adapted therapies that improve survival in high-risk neuroblastoma (Brodeur et al., 1984; Seeger et al., 1985). It supports precision oncology by distinguishing hyperdiploid low-risk tumors from those with segmental aberrations requiring intensive treatment (Maris, 2010). The INRG classification system uses these profiles for global treatment standardization (Cohn et al., 2008).
Key Research Challenges
Intratumor Heterogeneity Detection
Tumors exhibit variable genomic profiles within the same patient, complicating single-biopsy analyses. Brodeur (2003) notes biological enigmas in heterogeneity driving progression. Advanced sequencing is needed to map clonal evolution.
Linking Genomics to Prognosis
Correlating specific aberrations like N-myc copies to survival remains imprecise across cohorts. Seeger et al. (1985) found amplification predicts rapid progression, but thresholds vary. Integrative multi-omics data integration is required.
Actionable Target Identification
Few aberrations yield direct therapies despite profiling advances. Brodeur et al. (1984) established N-myc as a marker, but translation to inhibitors lags. Clinical trial designs must validate targets.
Essential Papers
The 2007 WHO Classification of Tumours of the Central Nervous System
David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler et al. · 2007 · Acta Neuropathologica · 4.6K citations
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Michael Höckel, Peter Vaupel · 2001 · JNCI Journal of the National Cancer Institute · 2.6K citations
Tissue hypoxia results from an inadequate supply of oxygen (O(2)) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for ...
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
G M Brodeur, Jon Pritchard, Frank Berthold et al. · 1993 · Journal of Clinical Oncology · 2.3K citations
PURPOSE AND METHODS: Based on preliminary experience, there was a need for modifications and clarifications in the International Neuroblastoma Staging System (INSS) and International Neuroblastoma ...
Amplification of N- <i>myc</i> in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab et al. · 1984 · Science · 2.3K citations
A domain of DNA designated N- myc is amplified 20- to 140-fold in human neuroblastoma cell lines but not in cell lines from other tumor types. N- myc has now been found to be amplified in neuroblas...
Neuroblastoma: biological insights into a clinical enigma
Garrett M. Brodeur · 2003 · Nature reviews. Cancer · 2.2K citations
Neuroblastoma
John M. Maris, Michael D. Hogarty, Rochelle Bagatell et al. · 2007 · The Lancet · 2.0K citations
Association of Multiple Copies of the N-<i>myc</i>Oncogene with Rapid Progression of Neuroblastomas
Robert C. Seeger, Garrett M. Brodeur, Harland N. Sather et al. · 1985 · New England Journal of Medicine · 2.0K citations
Eighty-nine patients with untreated primary neuroblastomas were studied to determine the relation between the number of copies of the N-myc oncogene and survival without disease progression. Genomi...
Reading Guide
Foundational Papers
Start with Brodeur et al. (1984) for N-myc amplification discovery, then Seeger et al. (1985) for prognostic correlations, and Brodeur (2003) for biological overview.
Recent Advances
Study Maris (2010, 1936 citations) for advances and Cohn et al. (2008, 1832 citations) for INRG classification integrating genomics.
Core Methods
Copy number variation via array CGH or WGS; FISH for N-myc; integrative risk scoring per INRG (Cohn et al., 2008).
How PapersFlow Helps You Research Neuroblastoma Genomic Profiling
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to trace N-myc amplification studies from Brodeur et al. (1984), revealing 2255 citing papers on genomic risk factors. exaSearch uncovers recent integrative analyses, while findSimilarPapers expands to INRG profiling (Cohn et al., 2008).
Analyze & Verify
Analysis Agent applies readPaperContent to extract copy number data from Seeger et al. (1985), then runPythonAnalysis with pandas to quantify N-myc copy correlations across cohorts. verifyResponse (CoVe) and GRADE grading statistically verify claims like amplification thresholds, reducing hallucination in heterogeneity assessments.
Synthesize & Write
Synthesis Agent detects gaps in hyperdiploidy-outcome links, flagging contradictions between Brodeur (2003) and Maris (2010). Writing Agent uses latexEditText, latexSyncCitations for INRG data (Cohn et al., 2008), and latexCompile to generate risk stratification tables; exportMermaid diagrams chromosome aberration flows.
Use Cases
"Run statistical analysis on N-myc amplification survival data from classic neuroblastoma papers."
Research Agent → searchPapers('N-myc neuroblastoma') → Analysis Agent → readPaperContent(Seeger 1985) → runPythonAnalysis(pandas survival curves, matplotlib plots) → GRADE-verified Kaplan-Meier output with p-values.
"Draft LaTeX review section on genomic risk groups with citations."
Synthesis Agent → gap detection(Brodeur 2003 + Cohn 2008) → Writing Agent → latexEditText('INRG profiling') → latexSyncCitations(10 papers) → latexCompile → PDF with formatted tables.
"Find code for neuroblastoma genome analysis pipelines."
Research Agent → searchPapers('neuroblastoma WGS pipeline') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → exportCsv of repo scripts for copy number analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ N-myc papers: searchPapers → citationGraph → DeepScan 7-steps with CoVe checkpoints on aberration-prognosis links. Theorizer generates hypotheses on heterogeneity from Brodeur (2003), chaining readPaperContent → runPythonAnalysis → synthesis. DeepScan verifies INRG claims (Cohn et al., 2008) via GRADE.
Frequently Asked Questions
What is neuroblastoma genomic profiling?
It uses sequencing to detect hyperdiploidy and aberrations like N-myc amplification for risk assessment (Brodeur et al., 1984).
What are key methods in this subtopic?
Whole-genome sequencing identifies segmental aberrations; FISH quantifies N-myc copies correlating to stage (Seeger et al., 1985).
What are seminal papers?
Brodeur et al. (1984, 2255 citations) discovered N-myc amplification; Cohn et al. (2008, 1832 citations) defined INRG using profiles.
What open problems exist?
Mapping intratumor heterogeneity and actionable non-N-myc targets remain unsolved (Brodeur, 2003).
Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroblastoma Genomic Profiling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers